Resources

Investor
FAQs

Jade Biosciences is headquartered at 221 Crescent Street, Building 23, Suite 105 in Waltham, Massachusetts, 02453.

Jade Biosciences is incorporated in the state of Nevada.

Jade Biosciences’ auditor is PricewaterhouseCoopers LLP.

Jade Biosciences began trading on Nasdaq under the ticker symbol JBIO on April 29, 2025. 

Jade Biosciences’ fiscal year ends on December 31.

Jade Biosciences’ common stock is traded on the Nasdaq Capital Market under the ticker symbol JBIO.

Jade Biosciences does not currently pay recurring dividends. However, in connection with its merger with Aerovate Therapeutics, Inc. (“Aerovate”) a special one-time cash dividend of approximately $2.40 per share was distributed to pre-merger Aerovate stockholders of record as of April 25, 2025. Please refer to our SEC filings available on the Investors section of JadeBiosciences.com.

Jade Biosciences has appointed Computershare as its stock transfer agent.

You can contact Computershare directly for assistance using one of the methods below:

No, Jade Biosciences does not have a direct stock purchase plan or any similar program. Shares of Jade Biosciences' common stock can be purchased through any registered broker.

Following the reverse stock split and merger with Aerovate, the CUSIP number for Jade Biosciences’ common stock is 008064206.

You can access all SEC filings at www.sec.gov by searching for “Jade Biosciences, Inc.” or using the ticker symbol JBIO. Filings are also available on the Investors section of JadeBiosciences.com.

On April 28, 2025, Jade Biosciences completed a merger with Aerovate. Immediately prior to the closing of the merger, Aerovate effected a 1-for-35 reverse stock split. This means every 35 shares of Aerovate common stock outstanding immediately prior to the merger were combined and reclassified into 1 share. In addition, stockholders of Aerovate common stock as of April 25, 2025 were entitled to receive a special cash dividend of approximately $2.40 per share on a pre-reverse stock split basis, or $84.00 per share on a post-reverse stock split basis, which was paid after the merger with Jade Biosciences closed. After the dividend, the stock price was correspondingly reduced to begin trading at $12.74 on April 29, 2025. The new combined company operates as Jade Biosciences, Inc., trading under the ticker symbol JBIO on Nasdaq.

Visit the Investors section of JadeBiosciences.com and submit your email to receive the latest updates and filings.

Email the Jade Investor Relations team at IR@JadeBiosciences.com.